{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-23-001644","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2023-08-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.677318+00:00","generated_at":"2026-06-11T02:49:37.141769+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Lexaria regains Nasdaq minimum bid price compliance; plans reverse split meeting","bullets":["Received Nasdaq letter confirming bid price >=$1.00 for 10 consecutive days through Aug 23, 2023.","Regained compliance with Nasdaq Listing Rule 5550(a)(2) for continued listing.","Company called special meeting to approve possible reverse stock split by May 31, 2024.","Intends to proceed with reverse split proposal to enable quick future compliance and attract investment."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-23-001644","json":"https://secwatch.observer/filing/0001640334-23-001644.json","markdown":"https://secwatch.observer/filing/0001640334-23-001644.md","text":"https://secwatch.observer/filing/0001640334-23-001644.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423001644/0001640334-23-001644-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423001644/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T02:49:37.141769+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}